Selected article for: "human respiratory infection and major cause"

Author: Chen, Yu; Deng, Xiaoling; Deng, Junfang; Zhou, Jiehua; Ren, Yuping; Liu, Shengxuan; Prusak, Deborah J.; Wood, Thomas G.; Bao, Xiaoyong
Title: Functional motifs responsible for human metapneumovirus M2-2-mediated innate immune evasion
  • Cord-id: hhgnaec3
  • Document date: 2016_12_31
  • ID: hhgnaec3
    Snippet: Abstract Human metapneumovirus (hMPV) is a major cause of lower respiratory infection in young children. Repeated infections occur throughout life, but its immune evasion mechanisms are largely unknown. We recently found that hMPV M2-2 protein elicits immune evasion by targeting mitochondrial antiviral-signaling protein (MAVS), an antiviral signaling molecule. However, the molecular mechanisms underlying such inhibition are not known. Our mutagenesis studies revealed that PDZ-binding motifs, 29-
    Document: Abstract Human metapneumovirus (hMPV) is a major cause of lower respiratory infection in young children. Repeated infections occur throughout life, but its immune evasion mechanisms are largely unknown. We recently found that hMPV M2-2 protein elicits immune evasion by targeting mitochondrial antiviral-signaling protein (MAVS), an antiviral signaling molecule. However, the molecular mechanisms underlying such inhibition are not known. Our mutagenesis studies revealed that PDZ-binding motifs, 29-DEMI-32 and 39-KEALSDGI-46, located in an immune inhibitory region of M2-2, are responsible for M2-2-mediated immune evasion. We also found both motifs prevent TRAF5 and TRAF6, the MAVS downstream adaptors, to be recruited to MAVS, while the motif 39-KEALSDGI-46 also blocks TRAF3 migrating to MAVS. In parallel, these TRAFs are important in activating transcription factors NF-kB and/or IRF-3 by hMPV. Our findings collectively demonstrate that M2-2 uses its PDZ motifs to launch the hMPV immune evasion through blocking the interaction of MAVS and its downstream TRAFs.

    Search related documents:
    Co phrase search for related documents
    • activation control and adaptive immune response: 1, 2, 3
    • activation control and loading control: 1, 2
    • activity measurement and acute phase: 1, 2, 3
    • activity measurement and adaptive immune response: 1
    • activity measurement and luciferase activity measurement: 1
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and additional insight: 1
    • acute phase and luciferase reporter: 1
    • acute phase and luciferase reporter assay: 1
    • adaptive immune response and luciferase reporter: 1
    • adaptive immune response and luciferase reporter assay: 1